Regadenoson long-lasting use induced tachyarrythmia

J Nucl Cardiol. 2019 Jun;26(3):1036-1039. doi: 10.1007/s12350-018-01561-3. Epub 2018 Dec 18.

Authors

Carlos Ramos-Font¹, Amelia Jimenez-Heffernan², Antonio González Jimenez³, Mahsa Rashki³, Jose Manuel Llamas Elvira³

Affiliations

¹ Nuclear Medicine Department, Hospital Universitario Virgen de las Nieves, Avd de las Fuerzas Armadas 2, Granada, Spain. carlos.ramos.font.sspa@juntadeandalucia.es.
² Nuclear Medicine Department, Hospital Juan Ramon Jimenez, Ronda Norte sn, Huelva, Spain.
³ Nuclear Medicine Department, Hospital Universitario Virgen de las Nieves, Avd de las Fuerzas Armadas 2, Granada, Spain.

PMID: 30565060
DOI: 10.1007/s12350-018-01561-3

No abstract available

Publication types

Case Reports

MeSH terms

Adenosine A2 Receptor Agonists / administration & dosage
Adenosine A2 Receptor Agonists / adverse effects*
Aged
Drug Administration Schedule
Female
Humans
Purines / administration & dosage
Purines / adverse effects*
Pyrazoles / administration & dosage
Pyrazoles / adverse effects*
Tachycardia, Supraventricular / chemically induced*
Tachycardia, Supraventricular / diagnosis*
Tachycardia, Supraventricular / therapy

Substances

Adenosine A2 Receptor Agonists
Purines
Pyrazoles
regadenoson